ACLX 001
Alternative Names: ACLX-001; ARC-T/sparX-BCMA - ArcellxLatest Information Update: 27 Jun 2025
At a glance
- Originator Arcellx
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Multiple myeloma
- No development reported Autoimmune disorders
Most Recent Events
- 27 Jun 2025 ACLX 001 is still in phase I trials for Multiple myeloma (Second-line therapy or greater) in USA (Parenteral) (Arcellx pipeline, June 2025) (NCT04155749)
- 28 Mar 2025 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (Parenteral)
- 27 May 2024 Arcellx has patent pending for ddBC and SparX technology in the US, Europe, Australia, Eurasia, Israeli, Indonesia, India, Japan, Mexico, Singapore, South Africa, Hong Kong, Monaco, Philippines, New Zealand, South Korea